$2.39 -0.05 (%) Brainstorm Cell Therapeutics Inc - NASDAQ

Sep. 26, 2016 | 03:12 PM

Partner Headlines

  1. Brainstorm Cell Therapeutics ALS Trial Shows Stem Cell Treatment Inhibits Disease Progression in 87% of Patients

    Benzinga | Jan. 11, 2016 | 18:44PM EST
  2. Mid-Morning Market Update: Markets Open Higher; Shire To Acquire Baxalta For $32B

    Benzinga | Jan. 11, 2016 | 10:07AM EST
  3. BrainStorm Cell Therapeutics Names Dr. Revital Geffen-Aricha as VP of R&D

    Benzinga | Dec. 7, 2015 | 04:07AM EST
  4. BrainStorm and Octane Biotech Announce Success in Cocoon Application Development Based on Customized Bioreactor for NurOwn® Stem Cells

    Benzinga | Dec. 1, 2015 | 08:10AM EST
  5. BrainStorm Awarded Additional $735K Non-Dilutive Grant for 2015 from Israel's Office of the Chief Scientist

    Benzinga | Nov. 30, 2015 | 04:10AM EST
  6. BrainStorm Announces Treatment of Final Patient in US Multicenter Double Blinded Phase 2 ALS Trial

    Benzinga | Oct. 7, 2015 | 09:37AM EST
  7. UPDATE: BrainStorm Cell Therapeutics Reports Closing of Enrollment in Phase 2 Trial of NurOwn in ALS

    Benzinga | Aug. 11, 2015 | 08:09AM EST
  8. Morning Market Gainers

    Benzinga | Apr. 14, 2015 | 09:42AM EST
  9. BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase 2a Clinical Data

    Benzinga | Apr. 14, 2015 | 07:02AM EST
  10. What Investors Are Looking At In The Stem Cell Sector

    Benzinga | Jan. 13, 2015 | 11:48AM EST
  11. Morning Market Losers

    Benzinga | Jan. 5, 2015 | 09:57AM EST
  12. Monday #PreMarket Movers: Conatus Pharmaceuticals, Brainstorm Cell Therapeutics And More

    Benzinga | Jan. 5, 2015 | 09:31AM EST
  13. Stocks Hitting 52-Week Highs

    Benzinga | Jan. 2, 2015 | 10:18AM EST
  14. Morning Market Movers

    Benzinga | Jan. 2, 2015 | 09:39AM EST
  15. Brainstorm Cell Therapeutics Soars 45%

    Benzinga | Jan. 2, 2015 | 08:57AM EST
  16. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 2, 2015 | 08:38AM EST
Trading Center